Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
← catalyst calendarSponsored by Adagene Inc (industry) · ADAG — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
14actual
Sites
2
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-13 | actual | When the study began enrolling |
| Primary completion | 2025-06-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced/Metastatic Solid Tumors
Intervention
- Drug: ADG206
Primary outcomes
what the primary-completion date above is the date OFNumber of participants experiencing dose-limiting toxicities escalating dose levels
measured At the end of Cycle 1 (each cycle is 21 days)
Number of participants with adverse events (AE)
measured At the end of 90 days post last dose (each cycle is 21 days)
Maximum administered dose (MAD) of ADG206
measured At the end of the last dose (each cycle is 21 days)
Maximum tolerated dose (MTD) of ADG 206
measured At the end of the last dose (each cycle is 21 days)
Recommended Phase 2 dose (RP2D) of ADG206
measured At the end of the last dose (each cycle is 21 days)
Publications
- PMID 38172595 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ADAG's whole pipeline · Catalyst calendar · Every registered study · What changed